MENU

Research

Dr. Crompton is a physician-scientist conducting translational research in pediatric solid tumors and other rare cancers. His laboratory program focuses on utilizing proteomic and genomic approaches to expand our understanding of cancer biology and identify novel treatment approaches for pediatric sarcomas. One goal of his laboratory is to validate the use of specific tyrosine kinase inhibitors in combination with other targeted agents and chemotherapy in the treatment of Ewing sarcoma. Dr. Crompton’s group utilizes cell line models and patient-derived xenograft models to identify and validate combinations of drugs that have synergistic activity against Ewing sarcoma cell growth.

Another goal of Dr. Crompton’s laboratory is to develop new non-invasive tumor profiling techniques to facilitate the quantification of disease burden, monitoring of clinical response, and for discovering clinically relevant patterns of tumor evolution. We have developed novel next-generation sequencing assays to detect and quantify circulating tumor DNA in the blood of patients with the most common types of pediatric sarcomas. We are focused on adapting these “liquid biopsy” techniques to aid in the diagnosis of sarcomas, quantification of disease burden, and assessing response to therapy.

At Dana-Farber Cancer Institute and Boston Children’s Hospital, Dr. Crompton has also implemented a systematic approach to collecting tumor and blood samples from patients with pediatric solid tumors. These efforts have contributed to the generation of new cancer cell lines, patient-derived xenograft models, and a better understanding the genomic landscape of pediatric cancers. He is also helping to lead a national effort to implement newer collection strategies for sarcoma patients enrolled on Children’s Oncology Group studies which enroll patients with pediatric sarcomas from throughout the country. Clinically, Dr. Crompton is a pediatric oncologist with expertise in caring for patients with pediatric solid tumor malignancies and pediatric cancer predispositions.